# Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Study · id `cardio:ct-nct06055452` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06055452](<https://clinicaltrials.gov/study/NCT06055452>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06055452

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT06055452. Randomized; quadruple masking; primary purpose prevention. Start 2024-01-19 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT06055452, source copy `cardio:ctgov-nct06055452-2026-03-05`, retrieved 2026-10-26)
- Started: 2024-01-19 (actual) (ClinicalTrials.gov record NCT06055452, source copy `cardio:ctgov-nct06055452-2026-03-05`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06055452, source copy `cardio:ctgov-nct06055452-2026-03-05`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06055452, source copy `cardio:ctgov-nct06055452-2026-03-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06055452, source copy `cardio:ctgov-nct06055452-2026-03-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06055452-2026-03-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
- Condition: Pre-Heart Failure
- Condition: Hypertension
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Placebo
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: 19e62c70355c3b9c0945a344bd906019f581e74a440a845370d84c7446fdd7c7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
